What are P2X7 receptor antagonist drugs?

P2X7 receptor antagonist drugs are pharmacologic agents that share a common mechanism (typically targeting P2X7). 0 are currently marketed, with 5 more in clinical development.

P2X7 receptor antagonist

0 marketed 4 in Phase 3 1 in Phase 2

This page covers all P2X7 receptor antagonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting P2X7.

Targets

P2X7

Phase 3 pipeline (4)

OPC-6535 Tablets (drug) · Otsuka Pharmaceutical Development & Commercialization, Inc. · Immunology
OPC-6535 is a selective antagonist of the P2X7 receptor, an ATP-gated ion channel involved in inflammatory and immune responses.
OPC-6535 · Otsuka Pharmaceutical Co., Ltd. · Neurology / Pain
OPC-6535 is a selective antagonist of the P2X7 receptor, which modulates purinergic signaling involved in inflammatory and immune responses.
GW406381 · GlaxoSmithKline · Immunology / Neurology
GW406381 is a selective antagonist of the P2X7 receptor, an ATP-gated ion channel involved in inflammatory and immune responses.
GW685698 · GlaxoSmithKline · Immunology
GW685698 is a selective antagonist of the P2X7 receptor, an ATP-gated ion channel involved in inflammatory and immune responses.

Phase 2 pipeline (1)

JTE-451 Tablets · Akros Pharma Inc. · Immunology
JTE-451 is a selective antagonist of the P2X7 receptor, which modulates immune cell activation and inflammatory responses.